NAMSAL: Wk 192 Results of Dolutegravir-Based vs Low-Dose Efavirenz-Based Regimens as First-line ART in Cameroon

Source: CCO Official Conference Coverage: Clinical Impact of New HIV Data From AIDS 2022
Download Slideset
July 29-August 2, 2022; Montreal, Quebec
Both DTG 50 mg plus 3TC/TDF and EFV 400 mg plus 3TC/TDF regimens effective and safe for treatment-naive PWH in Cameroon, with higher rates of virologic suppression over time and more weight gain observed with DTG-based regimen.
Format: Microsoft PowerPoint (.ppt)
File Size: 265 KB
Released: August 2, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings